Cardiac sarcoidosis – management and prognosis (RCD code: III‑3A.3)
Journal Title: Journal of Rare Cardiovascular Diseases - Year 2017, Vol 3, Issue 2
Abstract
Sarcoidosis is a systemic, granulomatous disease of unknown etiology. Cardiac involvement in the course of sarcoidosis occurs in 5% of patients. However, about 25% of patient with systemic/pulmonary sarcoidosis might present with asymptomatic myocardial injury. The main manifestations of cardiac sarcoidosis are conduction abnormalities, ventricular arrhythmias and heart failure. Diagnosis of cardiac sarcoidosis remains a challenge for physicians. Treatment should be introduced at the time of diagnosis to prevent potentially lethal progression of cardiac disease. Steroids are the first drugs of choice. Additional anti‑sarcoidosis agents are used as alternatives or to reduce the steroids dose. Some patients require implantation of a cardioverter‑defibrillator for the prevention of sudden cardiac death. Patients with refractory ventricular tachyarrhythmia or severe, intractable heart failure unresponsive to optimal pharmacotherapy, require heart transplantation. Prognosis in cardiac sarcoidosis is highly variable, dependent on location and severity of heart involvement. This article reviews current diagnostic and therapeutic recommendations for cardiac sarcoidosis. JRCD 2017; 3 (2): 37–43
Authors and Affiliations
Justyna Błaut-Jurkowska, Magdalena Kaźnica-Wiatr, Klaudia Knap, Lidia Tomkiewicz- Pająk, Piotr Podolec, Maria Olszowska
Keywords
Related Articles
- EP ID EP248057
- DOI 10.20418/jrcd.vol3no2.260
- Views 97
- Downloads 0
Journal of Rare Cardiovascular Diseases: “Conquering new territories” – a new educational program on rare diseases for medical acolytes
Dear Readers,Nowadays, we witness dramatic changes in the perception of rare diseases. Thanks to the European Union(EU) regulations but more importantly due to increasing pressure from the spontaneous patients’ organiza...
2nd International Conference on Rare Cardiovascular Diseases (Krakow, October 16–17, 2014)
The 2nd International Conference on Rare Cardiovascular Diseases was organized by the Krakow CRCD between 16th and 17th October 2014 at the John Paul II Hospital premises. The two-days Conference’s program was diverse, e...
Pulmonary arterial hypertension after systemic‑to‑pulmonary shunt correction (RCD code: II-1A.4d)
Pulmonary arterial hypertension develops in a significant number of patients with congenital heart diseases. Congenital heart diseases predispose to pulmonary vascular remodeling as a result of increased pulmonary blood...
JRCD is now included in the J‐Gate database, Free Medical Journals list, and JournalTOCs
We present to you the first issue of Journal of Rare Cardiovascular Diseases (JRCD) for 2018.
Electrocardiographic abnormalities in patients with pulmonary sarcoidosis (RCD code: III)
Sarcoidosis is a systemic inflammatory disease characterized by the presence of noncaseating granulomas. Etiology of the disease remains unknown. From 3.7% to 54.9% patients with extra‑cardiac sarcoidosis have asymptomat...